DBV expects cash runway into Q3 2027 as it advances sequential FDA reviews for VIASKIN Peanut BLAs

• "The highlight of the quarter was the filing of our BLA in 4 to 7-year olds" (CEO & Director Daniel Tassé).
• "In tandem with this important regulatory work, DBV's manufacturing and

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.